REHABILITATION ASSESSMENT METHODS FOR ONCOLOGY PATIENTS WITH CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
DOI:
https://doi.org/10.32782/2221-1217-2026-1-04Keywords:
chemotherapy-induced peripheral neuropathy, oncology rehabilitation, physical therapy, assessment methods, quality of life, ICFAbstract
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and clinically significant complications of systemic anticancer treatment, substantially limiting functional capacity, mobility, independence in self-care, and overall quality of life of oncology patients. The heterogeneity of clinical manifestations of CIPN, their gradual progression, and frequent subclinical presentation at early stages determine the need for a standardized, multidomain approach to rehabilitation assessment. The aim of this study was to analyze contemporary methods for assessing CIPN symptoms and tools for monitoring the effectiveness of physical therapy interventions in patients with oncological diseases.
Methods. An analysis and synthesis of scientific sources from the Scopus, PubMed, Google Scholar, and other databases were conducted, focusing on clinical, patient-reported, and functional assessment methods for CIPN.
Results. It was established that optimal assessment of CIPN is based on a combination of patient-reported outcome measures (FACT/GOG-Ntx, EORTC QLQ-CIPN20, CIPNAT), neuropathic pain scales (DN4, LANSS, NPS), generic quality-of-life instruments (EORTC QLQ-C30, WHOQOL-BREF, SF-36, EQ-5D), as well as clinical neurological examination and standardized functional tests. Particular importance is attributed to the assessment of balance, mobility, gait, muscle strength, fine motor skills, and activities of daily living, which allows identification of activity limitations and participation restrictions in accordance with the domains of the International Classification of Functioning, Disability and Health (ICF).
Conclusions. Comprehensive assessment of patients with CIPN using validated instruments and functional tests is a prerequisite for the timely detection of neurotoxic complications, justification of individualized physical therapy programs, and evaluation of their effectiveness within the oncology rehabilitation framework.
References
1. Ганноцька А., Зотов О. Профілактика та лікування периферичної нейропатії, індукованої хіміотерапією (огляд літератури). Practical Oncology (PO). 2024. Т. 6. № 2. С. 31–38. URL: https://oncology.zaslavsky.com.ua/index.php/journal/article/view/91 DOI: https://doi.org/10.22141/2663-3272.6.2.2023.91
2. Гриньків А. М., Бас О. А., Гриньків М. Я., Музика Ф. В., Шпарик Я. В. Сенсорні та моторні порушення при периферійній нейропатії, індукованій хіміотерапією, у онкологічних пацієнтів: показання до фізичної терапії. Public Health Journal. 2025. Т. 1. № 7. С. 67–76. https://doi.org/10.32782/pub.health.2025.1.10 DOI: https://doi.org/10.32782/pub.health.2025.1.10
3. Andersen Hammond E., Pitz M., Shay B. L. Neuropathic pain in taxane-induced peripheral neuropathy: Evidence for exercise in treatment. Neurorehabilitation and Neural Repair. 2019. Vol. 33. P. 792–799. https://doi.org/10.1177/1545968319860486 DOI: https://doi.org/10.1177/1545968319860486
4. Backonja M. M., Attal N., Baron R., et al. Value of quantitative sensory testing in neurological and pain disorders. Neurology. 2013. Vol. 81, No. 16. P. 1–10. https://doi.org/10.1212/WNL.0b013e3182a9f5d9
5. Beaton D. E., Bombardier C., Guillemin F., Ferraz M. B. Guidelines for the process of cross-cultural adaptation of self-report measures. Spine. 2005. Vol. 25, No. 24. P. 3186–3191. https://doi.org/10.1097/00007632-200012150-00014 DOI: https://doi.org/10.1097/00007632-200012150-00014
6. Beijers A. J., Mols F., Vreugdenhil G. A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Supportive Care in Cancer. 2014. Vol. 22, No. 7. P. 1999–2007. https://doi.org/10.1007/s00520-014-2242-z DOI: https://doi.org/10.1007/s00520-014-2242-z
7. Belloni S., Magon A., Giacon C., et al. Peripheral neuropathy instruments for individuals with cancer: A COSMIN-based systematic review of measurement properties. Current Oncology. 2024. Vol. 31, No. 12. P. 7828–7851. https://doi.org/10.3390/curroncol31120577 DOI: https://doi.org/10.3390/curroncol31120577
8. Bennett M. I. The LANSS Pain Scale: The Leeds assessment of neuropathic symptoms and signs. Pain. 2001. Vol. 92, No. 1–2. P. 147–157. https://doi.org/10.1016/S0304-3959(00)00482-6 DOI: https://doi.org/10.1016/S0304-3959(00)00482-6
9. Bouhassira D., Attal N., Alchaar H., et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of the DN4 questionnaire. Pain. 2005. Vol. 114, No. 1–2. P. 29–36. https://doi.org/10.1016/j.pain.2004.12.010 DOI: https://doi.org/10.1016/j.pain.2004.12.010
10. Boyette-Davis J. A., Walters E. T., Dougherty P. M. Mechanisms involved in the development of chemotherapy-induced neuropathy. Pain Management. 2015. Vol. 5, No. 4. P. 285–296. https://doi.org/10.2217/pmt.15.19 DOI: https://doi.org/10.2217/pmt.15.19
11. Colvin L. A. Chemotherapy-induced peripheral neuropathy: Where are we now? Pain. 2019. Vol. 160 (Suppl. 1). P. S1–S10. https://doi.org/10.1097/j.pain.0000000000001540 DOI: https://doi.org/10.1097/j.pain.0000000000001540
12. Cruccu G., Truini A. Tools for assessing neuropathic pain. PLoS Medicine. 2009. Vol. 6, No. 4. e1000045. https://doi.org/10.1371/journal.pmed.1000045 DOI: https://doi.org/10.1371/journal.pmed.1000045
13. DeMyer W. Technique of the neurologic examination. 5th ed. New York: McGraw-Hill; 2003. 774 p.
14. EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy. 1990. Vol. 16, No. 3. P. 199–208. https://doi.org/10.1016/0168-8510(90)90421-9 DOI: https://doi.org/10.1016/0168-8510(90)90421-9
15. Fayers P. M., Machin D. Quality of life: The assessment, analysis and interpretation of patient-reported outcomes. Chichester: Wiley; 2007. https://doi.org/10.1002/9780470024522 DOI: https://doi.org/10.1002/9780470024522
16. Gilchrist L. S., Galantino M. L., Wampler M., Marchese V. G., Morris G. S., Ness K. K. A framework for assessment in oncology rehabilitation. Physical Therapy. 2009. Vol. 89, No. 3. P. 286–306. https://doi.org/10.2522/ptj.20070309 DOI: https://doi.org/10.2522/ptj.20070309
17. Gu Z., Chen C., Gu J., et al. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment – oxaliplatin subscale: A prospective cohort study. BMC Cancer. 2023. Vol. 23, No. 1. Art. 1109. https://doi.org/10.1186/s12885-023-11541-7 DOI: https://doi.org/10.1186/s12885-023-11541-7
18. Hershman D. L., Lacchetti C., Dworkin R. H., et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers. Journal of Clinical Oncology. 2014. Vol. 32, No. 18. P. 1941–1967. https://doi.org/10.1200/JCO.2013.54.0914 DOI: https://doi.org/10.1200/JCO.2013.54.0914
19. Hudak P. L., Amadio P. C., Bombardier C. Development of an upper extremity outcome measure: The DASH. American Journal of Industrial Medicine. 1996. Vol. 29, No. 6. P. 602–608. https://doi.org/10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L DOI: https://doi.org/10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L
20. Jensen T. S., Finnerup N. B. Allodynia and hyperalgesia in neuropathic pain. Lancet Neurology. 2014. Vol. 13, No. 9. P. 924–935. https://doi.org/10.1016/S1474-4422(14)70102-4 DOI: https://doi.org/10.1016/S1474-4422(14)70102-4
21. Kolb N. A., Smith A. G., Singleton J. R., et al. The association of chemotherapy-induced peripheral neuropathy symptoms and the risk of falling. JAMA Neurology. 2016. Vol. 73, No. 7. P. 860–866. https://doi.org/10.1001/jamaneurol.2016.0383 DOI: https://doi.org/10.1001/jamaneurol.2016.0383
22. Li Y., Chen H., Wang X., et al. Rehabilitation outcomes in chemotherapy-induced peripheral neuropathy: A systematic review. Disability and Rehabilitation. 2024. Vol. 46, No. 2. P. 215–228.
23. Loprinzi C. L., et al. Prevention and management of chemotherapy-induced peripheral neuropathy: ASCO guideline update. Journal of Clinical Oncology. 2020. Vol. 38. P. 3325–3348. https://doi.org/10.1200/JCO.20.01399 DOI: https://doi.org/10.1200/JCO.20.01399
24. Menz H. B., Morris M. E., Lord S. R. Foot and ankle characteristics associated with impaired balance. Journal of Gerontology. Series A. 2005. Vol. 60, No. 12. P. 1546–1552. https://doi.org/10.1093/gerona/60.12.1546 DOI: https://doi.org/10.1093/gerona/60.12.1546
25. Mols F., Beijers T., Vreugdenhil G., van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and quality of life. Supportive Care in Cancer. 2014. Vol. 22, No. 8. P. 2261–2269. https://doi.org/10.1007/s00520-014-2255-7 DOI: https://doi.org/10.1007/s00520-014-2255-7
26. Postma T. J., Aaronson N. K., Heimans J. J., et al. Development of the EORTC QLQ-CIPN20. European Journal of Cancer. 2005. Vol. 41, No. 8. P. 1135–1139. https://doi.org/10.1016/j.ejca.2005.02.012 DOI: https://doi.org/10.1016/j.ejca.2005.02.012
27. Preti K., Davis M. E. Chemotherapy-induced peripheral neuropathy: Assessment and treatment strategies. Clinical Journal of Oncology Nursing. 2024. Vol. 28, No. 4. P. 351–357. https://doi.org/10.1188/24.CJON.351-357 DOI: https://doi.org/10.1188/24.CJON.351-357
28. Rolke R., Magerl W., Campbell K. A., et al. Quantitative sensory testing: A comprehensive protocol. European Journal of Pain. 2006. Vol. 10, No. 1. P. 77–88. https://doi.org/10.1016/j.ejpain.2005.02.003 DOI: https://doi.org/10.1016/j.ejpain.2005.02.003
29. Shah V. V., Muzyka D., Guidarelli C., Sowalsky K., Horak F. B., Winters-Stone K. M. Chemotherapy-induced peripheral neuropathy and falls in cancer survivors related to digital balance and gait impairments. JCO Precision Oncology. 2024. Vol. 8. Art. e2300312. https://doi.org/10.1200/PO.23.00312 DOI: https://doi.org/10.1200/PO.23.00312
30. Shumway-Cook A., Woollacott M. Motor control: Translating research into clinical practice. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2007.
31. Staff N. P., Grisold A., Grisold W., Windebank A. J. Chemotherapy-induced peripheral neuropathy: A current review. Annals of Neurology. 2017. Vol. 81, No. 6. P. 772–781. https://doi.org/10.1002/ana.24951 DOI: https://doi.org/10.1002/ana.24951
32. Stoller S., Capozza S., Alberti P., Lustberg M., Kleckner I. R. Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN). Supportive Care in Cancer. 2023. Vol. 31, No. 5. Art. 293. https://doi.org/10.1007/s00520-023-07734-2 DOI: https://doi.org/10.1007/s00520-023-07734-2
33. Streckmann F., Zopf E. M., Lehmann H. C., et al. Exercise intervention studies in patients with peripheral neuropathy: A systematic review. Sports Medicine. 2014. Vol. 44, No. 9. P. 1289–1304. https://doi.org/10.1007/s40279-014-0207-5 DOI: https://doi.org/10.1007/s40279-014-0207-5
34. Tofthagen C. Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clinical Journal of Oncology Nursing. 2010. Vol. 14, No. 3. P. E22–E28. https://doi.org/10.1188/10.CJON.E22-E28 DOI: https://doi.org/10.1188/10.CJON.E22-E28
35. WHOQOL Group. Development of the WHOQOL-BREF. Psychological Medicine. 1998. Vol. 28, No. 3. P. 551–558. https://doi.org/10.1017/S0033291798006667 DOI: https://doi.org/10.1017/S0033291798006667
